224 related articles for article (PubMed ID: 26733670)
1. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.
Fisher OM; Lord SJ; Falkenback D; Clemons NJ; Eslick GD; Lord RV
Gut; 2017 Mar; 66(3):399-410. PubMed ID: 26733670
[TBL] [Abstract][Full Text] [Related]
2. The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: a meta-analysis.
Zhao Z; Wang P; Gao Y; He J
Cancer Med; 2017 Jan; 6(1):54-66. PubMed ID: 27882726
[TBL] [Abstract][Full Text] [Related]
3. Active human papillomavirus involvement in Barrett's dysplasia and oesophageal adenocarcinoma is characterized by wild-type p53 and aberrations of the retinoblastoma protein pathway.
Rajendra S; Yang T; Xuan W; Sharma P; Pavey D; Lee CS; Le S; Collins J; Wang B
Int J Cancer; 2017 Nov; 141(10):2037-2049. PubMed ID: 28722212
[TBL] [Abstract][Full Text] [Related]
4. TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value.
Soontrapornchai P; Elsaleh H; Joseph D; Hamdorf JM; House AK; Iacopetta B
Eur J Cancer; 1999 Nov; 35(12):1683-7. PubMed ID: 10674013
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis of HPV-positive versus HPV-negative oesophageal adenocarcinoma identifies a differential mutational landscape.
Rajendra S; Wang B; Merrett N; Sharma P; Humphris J; Lee HC; Wu J
J Med Genet; 2016 Apr; 53(4):227-31. PubMed ID: 26470716
[TBL] [Abstract][Full Text] [Related]
6. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
8. Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.
Ten Kate FJC; van Olphen SH; Bruno MJ; Wijnhoven BPL; van Lanschot JJB; Looijenga LHJ; Fitzgerald RC; Biermann K
Br J Surg; 2017 Sep; 104(10):1327-1337. PubMed ID: 28692180
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
[TBL] [Abstract][Full Text] [Related]
10. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study.
Madani K; Zhao R; Lim HJ; Casson AG
Eur J Cardiothorac Surg; 2010 Jun; 37(6):1427-32. PubMed ID: 20227286
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.
McCormick Matthews LH; Noble F; Tod J; Jaynes E; Harris S; Primrose JN; Ottensmeier C; Thomas GJ; Underwood TJ
Br J Cancer; 2015 Jun; 113(1):107-18. PubMed ID: 26110972
[TBL] [Abstract][Full Text] [Related]
14. Association Between TP53 Mutation and Prognosis in Wilms Tumor: A Meta-Analysis.
Lizhi L; Rongdong H; Shaohua H; Yingquan K; Huihuang X; Shan L; Kunbin T; Di X
Fetal Pediatr Pathol; 2021 Dec; 40(6):653-662. PubMed ID: 32066305
[No Abstract] [Full Text] [Related]
15. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
Liu DS; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
Gut; 2015 Oct; 64(10):1506-16. PubMed ID: 26187504
[TBL] [Abstract][Full Text] [Related]
16. The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.
Prins MJ; Ruurda JP; Lolkema MP; Sitarz R; Ten Kate FJ; van Hillegersberg R
J Clin Pathol; 2015 Jul; 68(7):529-35. PubMed ID: 25855799
[TBL] [Abstract][Full Text] [Related]
17. MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.
Allott EH; Lysaght J; Cathcart MC; Donohoe CL; Cummins R; McGarrigle SA; Kay E; Reynolds JV; Pidgeon GP
Mol Carcinog; 2013 Feb; 52(2):144-54. PubMed ID: 22121096
[TBL] [Abstract][Full Text] [Related]
18. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis.
Ren J; Li G; Ge J; Li X; Zhao Y
Dis Colon Rectum; 2012 Aug; 55(8):913-23. PubMed ID: 22810479
[TBL] [Abstract][Full Text] [Related]
19. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.
Tornesello ML; Buonaguro L; Buonaguro FM
Gynecol Oncol; 2013 Mar; 128(3):442-8. PubMed ID: 23168175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
